Right now, the US Drug Enforcement Administration (DEA) classifies copyright for a Program II drug, recognizing its substantial potential for abuse but nevertheless allowing its limited use for health-related needs. Having said that, existing pharmacoepidemiological tendencies propose that copyright may possibly soon reach The purpose exactly where